PIACENTINI, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.168
EU - Europa 13.219
AS - Asia 9.034
SA - Sud America 1.316
AF - Africa 218
OC - Oceania 67
Continente sconosciuto - Info sul continente non disponibili 23
Totale 44.045
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.885
IT - Italia 4.118
SG - Singapore 2.790
CN - Cina 2.751
GB - Regno Unito 2.428
IE - Irlanda 2.190
HK - Hong Kong 1.302
DE - Germania 1.100
BR - Brasile 1.043
SE - Svezia 1.019
VN - Vietnam 588
RU - Federazione Russa 468
UA - Ucraina 377
FR - Francia 333
FI - Finlandia 300
ID - Indonesia 257
TR - Turchia 256
IN - India 248
BG - Bulgaria 169
KR - Corea 163
CA - Canada 162
NL - Olanda 156
JP - Giappone 114
TW - Taiwan 104
AR - Argentina 103
PL - Polonia 83
MX - Messico 80
IQ - Iraq 75
ES - Italia 73
LT - Lituania 73
AU - Australia 64
BE - Belgio 60
ZA - Sudafrica 59
BD - Bangladesh 55
EG - Egitto 49
MY - Malesia 46
IR - Iran 42
PK - Pakistan 42
AT - Austria 41
CZ - Repubblica Ceca 39
EC - Ecuador 38
CO - Colombia 32
VE - Venezuela 31
CL - Cile 30
CH - Svizzera 24
RO - Romania 24
PH - Filippine 21
SA - Arabia Saudita 21
IL - Israele 19
PY - Paraguay 18
EU - Europa 17
AE - Emirati Arabi Uniti 16
GR - Grecia 16
MA - Marocco 16
MD - Moldavia 16
HU - Ungheria 15
KE - Kenya 15
UZ - Uzbekistan 15
AL - Albania 14
JO - Giordania 14
TN - Tunisia 12
NG - Nigeria 11
TH - Thailandia 11
AZ - Azerbaigian 10
DK - Danimarca 10
DO - Repubblica Dominicana 10
DZ - Algeria 10
ET - Etiopia 10
MK - Macedonia 10
LV - Lettonia 9
PE - Perù 9
SI - Slovenia 9
PT - Portogallo 8
BO - Bolivia 7
LB - Libano 7
NP - Nepal 7
PA - Panama 7
HN - Honduras 6
KZ - Kazakistan 6
MT - Malta 6
RS - Serbia 6
SY - Repubblica araba siriana 6
CR - Costa Rica 5
GH - Ghana 5
KG - Kirghizistan 5
LA - Repubblica Popolare Democratica del Laos 5
NO - Norvegia 5
AM - Armenia 4
AO - Angola 4
GE - Georgia 4
IS - Islanda 4
KH - Cambogia 4
SK - Slovacchia (Repubblica Slovacca) 4
TZ - Tanzania 4
AP - ???statistics.table.value.countryCode.AP??? 3
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
BW - Botswana 3
HR - Croazia 3
KW - Kuwait 3
Totale 43.975
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.317
Dublin 2.184
Ashburn 1.917
Singapore 1.880
Fairfield 1.752
Chandler 1.433
Southend 1.325
Hong Kong 1.266
Woodbridge 1.011
Houston 786
Dearborn 735
Seattle 718
Nyköping 668
Ann Arbor 666
Hefei 644
Wilmington 621
Jacksonville 604
Beijing 572
Cambridge 535
London 512
Dallas 484
New York 391
Milan 362
Los Angeles 343
Modena 309
Rome 257
Jakarta 224
Munich 209
Chicago 205
Ho Chi Minh City 187
Shanghai 186
The Dalles 181
San Diego 180
Helsinki 179
Princeton 174
Bologna 168
Sofia 168
Moscow 151
Eugene 141
Seoul 136
Council Bluffs 131
Izmir 130
Hanoi 118
Dong Ket 112
Fremont 104
Redwood City 104
São Paulo 102
Buffalo 89
Frankfurt am Main 79
Bremen 77
Columbus 77
Naples 73
Salt Lake City 71
Falls Church 67
Guangzhou 67
Tokyo 64
Warsaw 62
Phoenix 60
Reggio Emilia 59
Boardman 58
Brooklyn 58
Redondo Beach 57
Turin 56
Florence 51
Brussels 49
Orem 49
Bari 48
Tampa 48
Genoa 46
Parma 46
Turku 44
Norwalk 43
Nuremberg 41
Elk Grove Village 40
Atlanta 37
Ottawa 37
Palermo 36
San Giuliano Milanese 35
Lauterbourg 34
Montreal 34
Paris 34
Stockholm 34
Kent 33
Nanjing 33
Rio de Janeiro 33
Baghdad 32
Des Moines 32
Enfield 32
Toronto 32
Denver 30
Padova 30
Portsmouth 30
San Francisco 30
Johannesburg 29
Kunming 29
Porto Alegre 29
Boston 28
Chennai 28
Amsterdam 27
Poplar 27
Totale 29.986
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.019
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 520
Abemaciclib: eventi avversi e riduzione di dose. 462
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 436
Oxford Manuale di Medicina Clinica 433
RISULTATI DELLA RADIOTERAPIA PANENCEFALICA (WBRT) NELLE METASTASI CEREBRALI DA CARCINOMA DELLA MAMMELLA: STUDIO RETROSPETTIVO SUL RUOLO PROGNOSTICO DEI FATTORI BIOLOGICI 408
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 393
SVILUPPO DI IPOGAMMAGLOBULINEMIA IN PAZIENTI TRATTATI CON IMATINIB PER LEUCEMIA MIELOIDE CRONICA O TUMORI STROMALI GASTROINTESTINALI 383
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 383
GD2 expression in breast cancer. 380
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 372
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor 364
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 360
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 354
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 352
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 339
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 331
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 327
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 323
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 321
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 320
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 319
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial 319
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 318
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 315
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 312
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 312
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 309
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 308
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 306
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 302
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 302
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 298
Tumor Stroma Manipulation By MSC 296
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer. 296
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 294
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 291
Achievements and unmet needs in the management of advanced ovarian cancer 286
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 286
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 285
Molecular Profile, as detected with Mass-Array Spectrometry (Sequenom platform), in primary and metastatic breast carcinoma treated with Exemestane + Everolimus 283
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 282
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 281
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 280
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 278
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 275
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 275
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 270
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 269
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 268
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 267
Immune characterization of breast cancer metastases: prognostic implications. 267
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 262
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 261
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer 260
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 260
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 260
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 259
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 256
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 256
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 255
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 254
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 253
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 251
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 250
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 249
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 249
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 249
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 247
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 239
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 238
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 238
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 237
Breast Location for De Novo Extramedullary Myeloid Sarcoma 237
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 235
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer 234
Prognostic Factors for Breast Cancer: an Immunomorphological Update 233
Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study 231
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 230
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 230
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 228
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 228
Timing for starting second-line therapy in recurrent ovarian cancer 227
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 227
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 226
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 226
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 223
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 222
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 220
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 220
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 219
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 219
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 215
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 212
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 212
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 211
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 211
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 208
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 207
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 206
Totale 28.909
Salva come PNG Salva come JPEG
Categoria #
all - tutte 161.475
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 161.475
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.574 0 0 0 0 0 369 364 456 266 465 345 309
2021/20223.347 133 383 286 129 124 264 152 199 366 301 594 416
2022/20236.486 494 585 344 417 410 514 111 388 2.573 114 325 211
2023/20243.725 179 203 239 292 496 314 342 569 150 204 298 439
2024/20259.842 357 209 270 727 1.882 1.501 628 693 967 583 772 1.253
2025/20268.748 1.211 601 1.616 1.833 2.728 759 0 0 0 0 0 0
Totale 44.436